公开(公告)号：US06221396B1

公开(公告)日：2001-04-24

申请号：US09349034

申请日：1999-07-07

Applicant: Shouchung Chao ,  Wen-Pao Tseng ,  Hui-Fang Chang ,  David Chen ,  Shu-Bin Lu

Inventor： Shouchung Chao ,  Wen-Pao Tseng ,  Hui-Fang Chang ,  David Chen ,  Shu-Bin Lu

IPC: A61K932

CPC classification number: A61K9/5084 ,  A61K9/1676 ,  A61K9/5078 ,  A61K31/4468

Abstract: The present invention provides sustained release oral solid dosage forms of cisapride by using a multi-particulate system, which are bioavailable and can provide efficient blood level of cisapride over 24 hours. Unit dosage forms of cisapride which comprise a plurality of substrates containing sustained release cisapride, as well as pharmaceutical compositions containing the dosage forms, are also disclosed herein.

Abstract translation: 本发明通过使用生物可利用的多微粒体系提供西沙必利的缓释口服固体剂型，并可在24小时内提供西沙必利的有效血药浓度。 包含含有持续释放西沙必利的多种底物的西沙必利的单位剂量形式以及含有剂型的药物组合物也在本文中公开。

公开(公告)号：US06183777B2

公开(公告)日：2001-02-06

申请号：US09006856

申请日：1998-01-14

Applicant: Pao-Nien Chen ,  Chuan-Ming Lai ,  Shu-Jian Liu ,  Fan-Jung Liu ,  Shu-Bin Lu

Inventor： Pao-Nien Chen ,  Chuan-Ming Lai ,  Shu-Jian Liu ,  Fan-Jung Liu ,  Shu-Bin Lu

IPC: A61K924

CPC classification number: A61K31/00 ,  A61K9/209

Abstract: Disclosed is a controlled release tacrine dosage form, which comprises: (a) a core; (b) an inner active layer comprising tacrine and a binder; (c) a release-controlling layer comprising one or more release-controlling-film-forming polymer; and (d) an active overcoat comprising tacrine and a binder. Also disclosed is a process for preparing the controlled release dosage form.

Abstract translation: 公开了一种控释他克林剂型，其包括：（a）核心;（b）包含他克林和粘合剂的内部活性层;（c）包含一个或多个释放控制膜形成的释放控制层 聚合物; 和（d）包含他克林和粘合剂的活性外涂层。还公开了制备控释剂型的方法。

公开(公告)号：US5889051A

公开(公告)日：1999-03-30

申请号：US893265

申请日：1997-07-15

Applicant: David Chen ,  Rong-Jer Tsay ,  Hue-In Lin ,  Shu-Bin Lu

Inventor： David Chen ,  Rong-Jer Tsay ,  Hue-In Lin ,  Shu-Bin Lu

IPC: A61K9/14 ,  A61K31/215

CPC classification number: A61K9/146 ,  Y10S514/964

Abstract: A stable solid dispersion of prostaglandin drug, particularly Misoprostol, (.+-.)methyl 7-�3(.alpha.)-hydroxy-2-.beta.-(4 (RS)-4-hydroxy-4-methyl-trans-1-octen-1-yl)-oxycyclopent-1.alpha.-yl!heptanoate, comprising ammonio methacrylate copolymers. The ammonio methacrylate copolymers comprise Eudragit RS series, Eudragit RL series, Eudragit S, Eudragit L, and the mixture thereof. The stable solid dispersion is a sustained release type.

Abstract translation: 前列腺素药物稳定的固体分散体，特别是米索前列醇，7-（3-甲氧基-2-（4-（RS）-4-羟基-4-甲基 - 反式-1-辛烯 -1-基） - 环氧-1α-基]庚酸酯，其包含氨基甲基丙烯酸酯共聚物。 氨基甲基丙烯酸酯共聚物包括Eudragit RS系列，Eudragit RL系列，Eudragit S，Eudragit L及其混合物。 稳定的固体分散体是持续释放型。